Evolent Health price target lowered to $4 by Citigroup

Analysts cite challenges for the healthcare technology company

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

Citigroup analysts have lowered their price target for Evolent Health (NYSE:EVH) from $6 to $4, while maintaining a "buy" rating on the stock. The analysts cited ongoing challenges for the healthcare technology and services company, which has seen its stock price decline significantly over the past year.

Why it matters

Evolent Health's stock price has been volatile as the company navigates the shift to value-based care models in the healthcare industry. The lowered price target from a major investment bank signals continued uncertainty about the company's near-term prospects, even as analysts remain optimistic about its long-term potential.

The details

In a research note, Citigroup analysts said they were lowering their price target on Evolent Health due to "ongoing challenges" facing the company. The analysts maintained a "buy" rating on the stock, but the reduced price target of $4 represents a potential upside of just 19.94% from the company's previous closing price.

  • Citigroup issued the updated price target and research note on Thursday, February 26, 2026.

The players

Evolent Health

A U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs.

Citigroup

A major global investment bank and financial services corporation that provides research coverage and analysis on Evolent Health.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Evolent Health's stock price volatility reflects the broader challenges facing healthcare companies as the industry shifts towards value-based care models. While analysts remain optimistic about the company's long-term potential, near-term headwinds continue to create uncertainty around its performance.